Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry

BACKGROUND AND OBJECTIVES: Sacubitril/valsartan (SV, LCZ696), the first in class drug, called as angiotensin receptor-neprilysin inhibitor (ARNI) can reduce heart failure (HF) hospitalization and cardiovascular mortality. However, SV prescription rate remains still low despite current HF guideline r...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jaewon, Lee, Chan Joo, Park, Jin Joo, Lee, Sang Eun, Kim, Min-Seok, Cho, Hyun-Jai, Choi, Jin-Oh, Lee, Hae-Young, Hwang, Kyung-Kuk, Kim, Kye Hun, Yoo, Byung-Su, Choi, Dong-Ju, Baek, Sang Hong, Jeon, Eun-Seok, Kim, Jae-Joong, Cho, Myeong-Chan, Chae, Shung Chull, Oh, Byung-Hee, Kang, Seok-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Heart Failure 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536672/
https://www.ncbi.nlm.nih.gov/pubmed/36262737
http://dx.doi.org/10.36628/ijhf.2019.0007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536672/
https://www.ncbi.nlm.nih.gov/pubmed/36262737
http://dx.doi.org/10.36628/ijhf.2019.0007

Ejemplares similares